Introduction: Gall bladder cancer (GBC) is the commonest biliary tract cancer and the most common gastro-intestinal cancer among women in north Indian population. Angiogenesis plays an important role in growth, progression, and metastasis of tumors. Vascular endothelial growth factor (VEGF), platelet derived growth factor-B (PDGFB) and human epidermal growth factor receptor-2 (HER2) are potent mitogens belonging to a family of receptor tyrosine kinases, that are thought to participate in signal transduction mediating tumor cell proliferation. In the present study, we evaluated the association of functional polymorphisms in VEGF, PDGFB and HER2 genes with GBC progression and survival. Methods: VEGF -1154 G>A, -2578 C>A, PDGFB +286A>G and +1135A>C polymorphisms were investigated by amplification refractory mutation system (ARMS) PCR. VEGF +936C>T and HER2 Ile655Val polymorphisms by restriction fragment length polymorphism (PCR-RFLP) and VEGF-2549 Ins/Del by PCR in DNA extracted from venous blood of 80 GBC patients who were operated before 2010 (to ensure at least 5 years follow up) and in whom follow up data was available. Results: +286GA genotype of PDGFB showed significant risk protective association with regional lymph node metastasis (OR=0.27, p value=0.03). In Kaplan-Meir survival analysis, genotypes VEGF-1154 GA (Chi-square=10.18 and P=0.0006), +936 CC (Chi-square=7.332 and P=0.026) and PDGFB+1135CC (Chi-square=7.424 and p value=0.024) showed significantly longer survival but there was no significant survival correlation with HER2 polymorphism. Conclusion: VEGF and PDGFB gene polymorphisms may play a role in progression (lymph node metastasis) and survival in GBC.